Is Janus Henderson Small Cap Growth Alpha ETF ( JSML ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Should Janus Henderson Small Cap Growth Alpha ETF ( JSML ) Be on Your Investing Radar?
Style Box ETF report for ...
Why Halozyme Therapeutics ( HALO ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
After Golden Cross, Halozyme Therapeutics ( HALO ) 's Technical Outlook is Bright
Is it a good or bad thing when a stock experiences a golden cross technical event?
Here's Why Halozyme Therapeutics ( HALO ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What Does the Market Think About Halozyme Therapeutics? - Halozyme Therapeutics ( NASDAQ:HALO )
Halozyme Therapeutics's HALO short percent of float has fallen 5.58% since its last report. The company recently reported that it has 9.60 million shares sold short, which is 10.67% of all regular shares that are available for trading.
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
Halozyme ( HALO ) Q2 EPS Jumps 69%
Halozyme Therapeutics ( NASDAQ:HALO ) , a biotechnology company specializing in drug delivery innovations, released its second-quarter 2025 results on August 5, 2025. The quarter's headline is outperformance: EPS came in at $1.54 ( non-GAAP ) , surpassing the $1.24 non-GAAP consensus and EPS grew ...
Halozyme Therapeutics ( HALO ) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Arcutis Biotherapeutics, Inc. ( ARQT ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Therapeutics ( HALO ) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Halozyme Therapeutics ( NASDAQ:HALO )
Halozyme Therapeutics HALO has outperformed the market over the past 15 years by 2.72% on an annualized basis producing an average annual return of 14.99%. Currently, Halozyme Therapeutics has a market capitalization of $7.09 billion.
Why Halozyme Therapeutics ( HALO ) is Poised to Beat Earnings Estimates Again
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Halozyme Therapeutics ( HALO ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Halozyme Therapeutics ( HALO ) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Invesco S&P MidCap 400 GARP ETF ( GRPM ) Be on Your Investing Radar?
Style Box ETF report for ...
Is Invesco S&P MidCap 400 GARP ETF ( GRPM ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years - Halozyme Therapeutics ( NASDAQ:HALO )
Halozyme Therapeutics HALO has outperformed the market over the past 15 years by 2.0% on an annualized basis producing an average annual return of 14.27%. Currently, Halozyme Therapeutics has a market capitalization of $6.64 billion.
Alector Provides Executive Leadership Update - Alector ( NASDAQ:ALEC )
-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 ( GLOBE NEWSWIRE ) -- Alector, Inc.
Alector Provides Executive Leadership Update
-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 ( GLOBE NEWSWIRE ) -- Alector, Inc. ( Nasdaq: ALEC ) , a late-stage clinical biotechnology company focused on developing ...
Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Halozyme Therapeutics ( NASDAQ:HALO )
Halozyme Therapeutics HALO has outperformed the market over the past 15 years by 2.54% on an annualized basis producing an average annual return of 14.44%. Currently, Halozyme Therapeutics has a market capitalization of $6.72 billion.
Why Is Allogene Therapeutics ( ALLO ) Up 52.2% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Halozyme Therapeutics ( HALO ) Down 23.2% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Halozyme Therapeutics ( NASDAQ:HALO )
Halozyme Therapeutics HALO has outperformed the market over the past 5 years by 4.46% on an annualized basis producing an average annual return of 17.65%. Currently, Halozyme Therapeutics has a market capitalization of $6.59 billion.
4 Stocks With Strong Interest Coverage Ratios to Buy in June 2025
STRL, BJ, MOH, and HALO shine with strong interest coverage ratios, signaling solid fundamentals for June 2025.
What's Driving the Market Sentiment Around Halozyme Therapeutics? - Halozyme Therapeutics ( NASDAQ:HALO )
Halozyme Therapeutics's HALO short percent of float has risen 12.94% since its last report. The company recently reported that it has 10.69 million shares sold short, which is 11.87% of all regular shares that are available for trading.
3 Reasons Growth Investors Will Love Halozyme Therapeutics ( HALO )
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Price Over Earnings Overview: Halozyme Therapeutics - Halozyme Therapeutics ( NASDAQ:HALO )
Looking into the current session, Halozyme Therapeutics Inc. HALO shares are trading at $53.85, after a 1.05% drop. Over the past month, the stock decreased by 10.78%, but over the past year, it actually went up by 26.41%.
Implied Volatility Surging for Halozyme Therapeutics Stock Options
Investors need to pay close attention to HALO stock based on the movements in the options market lately.
New Strong Buy Stocks for May 28th
PHIO, FLNG, BWB, ALRS and HALO have been added to the Zacks Rank #1 (Strong Buy) List on May 28, 2025.
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - AMETEK ( NYSE:AME ) , Ares Acquisition ( NYSE:AACT )
The Benzinga Stock Whisper Index highlights five stocks each week seeing more interest from readers than normal. Stocks in this week's list saw analyst upgrades and announced acquisitions. Memorial Day Special: Access your full investing command center with trade ideas, screeners, and expert ...
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.
ARMP Soars 72% in a Month Following Infectious Disease Study Success
Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday - Archer Aviation ( NYSE:ACHR ) , ACADIA Pharmaceuticals ( NASDAQ:ACAD )
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday. Shares of Evolv Technologies Holdings, Inc. EVLV rose sharply during Friday's session after the company announced preliminary first-quarter financial results. The company said it expects revenue growth of 40%+ in the ...
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
4 Stocks With Impressive Interest Coverage Ratio to Buy Now
STRL, AXS, MOH & HALO's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Crude Oil Gains 3%; US Inflation Eases In April - Affimed ( NASDAQ:AFMD ) , Halozyme Therapeutics ( NASDAQ:HALO )
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday. The Dow traded down 0.49% to 42,203.63 while the NASDAQ gained 1.74% to 19,033.50. The S&P 500 also rose, gaining, 0.86% to 5,894.52. Information technology shares jumped by 2.3% on ...
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
